Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced new data on preparing AAV-based gene therapy programs to… Read More »Opus Genetics Inc., has announced new data on the potential of gene therapy treatments from RDH12- and MERTK-associated retinal degenerations.
Researchers at the Department of Ophthalmology, Copenhagen University Hospital – Rigshospitalet-Glostrup, Denmark, has reported a long-term follow-up study on the natural history of PRPF31-related retinitis… Read More »A 36-year follow up study on retinitis pigmentosa (RP) patients with a Nordic population of RP11 / PRPF31.
Researchers at the Shiley Eye Institute, University of California, San Diego, has reported results of AI (artificial intelligence) methods providing significantly accurate outcomes over manual… Read More »AI (artificial intelligence) study on multimodal images of RP patients shows significant impacts from both structural and functional evaluations.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the May 2nd, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »May 2nd, 2023 “EURETINA-Brief”© Issue No. 270
Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced preliminary safety and efficacy data of a Phase 1/2 study of “OCU400”,… Read More »Ocugen Inc., (NASDAQ: OCGN) has announced preliminary safety and efficacy data of a Phase 1/2 study for a modifier gene therapy candidate treating retinitis pigmentosa (RP)
Researchers at the Department of Ophthalmology, Zealand University Hospital and the University of Copenhagen, Denmark have found that Danish patients with geographic atrophy (GA) have… Read More »Geographic atrophy (GA) patients report quality of life (QoL) results on visual acuity and lesion size in a Danish cohort
Researchers at the Telethon Institute of Genetics and Medicine (TIGEM), Pozzuoli, Italy, has reported the results of 5,054 gene transcripts analysed from 218 IRD (inherited… Read More »A novel overview of the human retinal transcriptome may contribute missing heritability in IRD patients
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »April 16th, 2023 “EURETINA-Brief”© Issue No. 269
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), a clinical stage company based in Lexington, Massachusetts, has reported the completion of the enrollment of a Phase 2 clinical… Read More »Aldeyra Therapeutics Inc., (NASDAQ: ALDX) reports the completion of enrollment in a Phase 2 study for methotrexate to treat Pro23His retinitis pigmentosa (RP)
Researchers at the Ophthalmology Unit, Fondazione Policlinico Universitario Agostino in Rome, has reported that pathogenic variants in the eyes shut homolog (EYS) gene are estimated… Read More »Retinitis pigmentosa arising from EYS gene mutations have reported novel insights from combined measurements for a RP stage score system (RP-SSS)
